Compare Fortinet Inc (FTNT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Sana Biotechnology Inc — how do they compare? Fortinet Inc trades at $160.88 (market cap $118.78B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Fortinet Inc is far larger — about 105.1× Sana Biotechnology Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| FTNT | SANA | |
|---|---|---|
Market Cap | $118.78B | $1.13B |
Sector | Technology | Health |
52-Week High | $168.29 | $5.92 |
52-Week Low | $75.23 | $2.68 |
Enterprise Value | $115.21B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $161.21, down 1.83% over 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $0.90 versus $0.746 expected, driven by robust demand for cybersecurity solutions amid AI-driven security needs. Revenue growth has accelerated from $4.4B in 2022 to $6.8B in 2025, with net income margins above 28%, though valuation ratios like P/E of 57.2 indicate premium pricing.
The outlook remains positive given consistent earnings beats and analyst consensus price target of $174.50, offering ~8% upside. Key risks include high valuation multiples, competitive pressures in cybersecurity, and negative net cash flow trends. Institutional sentiment is mixed with 42.65% buy ratings, but growth in AI security and SASE firewall adoption supports long-term potential.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
